Chronic migraine, Phase III data for Amgen/Novartis’ antibody now presented

Novartis today announced complete Phase II results showing the fully human monoclonal antibody named AMG 334 (erenumab) produced a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. Among trial participants, a significantly larger number of those receiving monthly subcutaneous product 70mg or 140mg experienced a 50% or more reduction in the number of migraine days compared with placebo. The new data will be presented at the EHMTIC congress, being held in Glasgow in these days. The study was conducted on 667 patients who had a baseline of approximately 18 migraine days per month. Results from the Phase III clinical trial are expected later this year. The product is being co-developed by Amgen and Novartis. (Source Novartis press release)